NCT04688164: A trial that was reported late by Relmada Therapeutics, Inc.
This trial has reported, although it was 107 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT04688164 |
|---|---|
| Title | A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment of Major Depressive Disorder (The RELIANCE-I Study) |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Jan. 8, 2021 |
| Completion date | Nov. 1, 2022 |
| Required reporting date | Nov. 1, 2023, midnight |
| Actual reporting date | Feb. 16, 2024 |
| Date last checked at ClinicalTrials.gov | April 24, 2025 |
| Days late | 107 |